Neumora Therapeutics, Inc. (NASDAQ:NMRA) Insider Sells $363,606.28 in Stock

Neumora Therapeutics, Inc. (NASDAQ:NMRA) insider Robert A. Lenz sold 30,788 shares of the business’s stock in a transaction that occurred on Tuesday, September 17th. The stock was sold at an average price of $11.81, for a total value of $363,606.28. Following the sale, the insider now directly owns 339,205 shares in the company, valued at $4,006,011.05. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink.

Neumora Therapeutics Stock Up 1.5 %

Shares of Neumora Therapeutics stock opened at $12.92 on Friday. The stock’s fifty day moving average is $11.74 and its two-hundred day moving average is $11.41. Neumora Therapeutics, Inc. has a 52 week low of $8.33 and a 52 week high of $21.00.

Neumora Therapeutics (NASDAQ:NMRA) last posted its quarterly earnings results on Tuesday, August 6th. The company reported ($0.37) EPS for the quarter, hitting analysts’ consensus estimates of ($0.37). As a group, research analysts predict that Neumora Therapeutics, Inc. will post -1.51 EPS for the current year.

Hedge Funds Weigh In On Neumora Therapeutics

A number of hedge funds have recently added to or reduced their stakes in the stock. Amalgamated Bank bought a new stake in shares of Neumora Therapeutics during the fourth quarter valued at approximately $29,000. Quarry LP purchased a new position in Neumora Therapeutics during the 2nd quarter worth $98,000. SkyOak Wealth LLC bought a new stake in Neumora Therapeutics during the 2nd quarter valued at $147,000. Principal Financial Group Inc. bought a new stake in Neumora Therapeutics during the 2nd quarter valued at $166,000. Finally, SG Americas Securities LLC purchased a new stake in shares of Neumora Therapeutics in the 2nd quarter worth $566,000. 47.65% of the stock is currently owned by institutional investors.

Analysts Set New Price Targets

A number of equities analysts have recently commented on NMRA shares. Needham & Company LLC reiterated a “buy” rating and issued a $23.00 target price on shares of Neumora Therapeutics in a report on Thursday, September 12th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $29.00 price objective on shares of Neumora Therapeutics in a research note on Wednesday, September 4th. Finally, Mizuho assumed coverage on shares of Neumora Therapeutics in a research report on Monday, July 8th. They set an “outperform” rating and a $20.00 price objective on the stock. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to data from MarketBeat.com, Neumora Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus target price of $22.11.

About Neumora Therapeutics

Neumora Therapeutics, Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder.